As of today (2026-07-08), the Trailing Annual Dividend Yield of Verrica Pharmaceuticals is 0.00%.
The historical rank and industry rank for Verrica Pharmaceuticals's Dividend Yield % or its related term are showing as below:
STU:1NE0's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.31 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1NE0 vs ENGN, PEPG, ONCY: Dividend Yield % Comparison
For the Biotechnology subindustry, Verrica Pharmaceuticals's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verrica Pharmaceuticals Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Verrica Pharmaceuticals's Dividend Yield % falls into.
Verrica Pharmaceuticals (STU:1NE0) has a Dividend Yield % of 0.00% as of Jul. 08, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Verrica Pharmaceuticals and its competitors. According to the industry distribution chart, Verrica Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry.
Is Verrica Pharmaceuticals' Dividend Yield % too high?
Verrica Pharmaceuticals' current Dividend Yield % is 0.00%. Based on the distribution chart, Verrica Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Verrica Pharmaceuticals has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Dividend Yield % compare to ENGN and PEPG?
According to the Biotechnology industry distribution chart, Verrica Pharmaceuticals ranks #999999 out of 153 companies for Dividend Yield %. This places Verrica Pharmaceuticals in the lower half of its industry. The industry median Dividend Yield % is 1.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.31, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Verrica Pharmaceuticals and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verrica Pharmaceuticals's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (STU:1NE0) is currently considered Possible Value Trap. The stock's GF Value™ is €12.59, compared to a current price of €5.31 — trading 57.8% below its estimated fair value. The current Dividend Yield % is 0.00%. Verrica Pharmaceuticals' overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Verrica Pharmaceuticals (STU:1NE0), the current Dividend Yield % is 0.00% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verrica Pharmaceuticals (STU:1NE0) Overvalued in 2026?
Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued.
The current stock price of €5.31 is trading 57.8% below its estimated GF Value™ of €12.59.
GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.
Key valuation signals for STU:1NE0:
Dividend Yield %: 0.00%
GF Value™: €12.59 vs. price of €5.31 (57.8% below fair value)
No single metric tells the full story. See the STU:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
45GF Score
Get the complete analysis for STU:1NE0
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1NE0 has been successfully added to your 
